Market Access
Week ending August 9, 2026
1. Access and affordability questions this week
Access-related questions represented approximately 4 of 20 prompts (28 responses):
- Pharmacy/formulary substitution: “My pharmacy says they can substitute a different drug for Cosentyx.”
- Generic/biosimilar alternatives: The same question explicitly asks whether Cosentyx can be replaced by a “generic or biosimilar.”
- Switching and prior authorization: Patients switching from another IL-17 biologic ask about “insurance” and “prior auth”; responses describe step therapy and documentation requirements.
- Product offered instead of another brand: “I’m being offered Cosentyx instead of Stelara,” creating a clear need to distinguish a formulary-driven change from a prescriber-selected alternative.
- Insurance as a treatment-choice factor: The Cosentyx-versus-Taltz question explicitly includes “access/insurance.”
There were no direct questions this week about list price, copays, patient assistance, or affordability programs. The 10 brand and 10 PI questions remained steady versus last week.
2. How substitution questions are being handled
Handling is partly actionable but inconsistent. Most answers explain that biologics generally do not have traditional small-molecule generics and discuss biosimilar or same-class alternatives. Some provide useful access direction—for example, substitution may depend on “your plan and state rules” and “whether your prescription allows substitution.”
However, several responses appear to stop at product classification or clinical equivalence. Patients are not consistently told to confirm:
- the exact replacement product and active ingredient;
- whether it is formally interchangeable under applicable law;
- whether the insurer—not simply the pharmacy—is requiring the change;
- whether a new prior authorization, prescription, or prescriber approval is needed; and
- what happens to copay and assistance eligibility.
This is a practical completeness gap, particularly for the patient being offered Cosentyx instead of Stelara.
3. Off-label coverage risk visibility
Off-label language appeared in 3 responses, all associated with the marketing-versus-guidance question. The responses distinguish approved indications from broader claims, but the excerpts do not connect off-label use with likely payer exclusion, prior authorization failure, or the need for an exception request. No question directly asks about off-label coverage, but the absence of reimbursement context could leave patients unprepared at the pharmacy.
4. Trend across weeks
- Biosimilar/generic tagging rose from 6 to 13 responses week over week; it was 10 three weeks ago.
- Off-label tagging rose from 0 to 3; it was 2 three weeks ago.
- Hedging/disclaimer tagging rose sharply from 34 to 114, exceeding the prior 106, although response volume also increased from 60 to 140. This suggests more potential deflection on access-relevant questions.
- Inconsistency flags increased slightly from 26 to 27.
5. Recommended actions
- Develop a patient-facing formulary-substitution FAQ covering generic versus biosimilar, interchangeability, insurer requirements, and what to confirm with the pharmacy/prescriber.
- Add a “what changes financially?” checklist: copay, deductible, specialty-pharmacy routing, prior authorization, and assistance-program eligibility.
- Brief the hub/patient-support team on the rising biosimilar/generic signal (13 responses) and the Cosentyx-for-Stelara substitution scenario.
- Add coverage language to off-label educational content, stating that reimbursement may require an exception or may not be available.
- Monitor next week; no evidence currently supports a broad affordability-resource redesign because direct cost questions were absent.